• Report Adverse Event or Product Quality Complaint
  • US Site
  • Global Site
AstraZeneca Medical Information
  • Therapy Areas
    • All Therapeutic Areas
    • Cardiovascular
    • Immunology
    • Infection
    • Metabolic
    • Oncology
    • Renal
    • Respiratory
    • Rare Disease (Alexion)
  • Medications
  • Resources
    • Congress Library
    • Disease Education
    • Pipeline
    • Clinical Trials
    • Open innovation
    • Access 360
    • Affordability Programs
    • Sample Closet
    • Medical Education Grant
    • Rare Disease (Alexion)
  • Connect
    • Find an MSL
    • Request an MSL
    • Submit an MIR
    • Give Feedback
User
  • Login to My AZmedical
  • Register for My AZmedical

Search Medical Information

American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) 2025 Annual Meeting

October 29 to November 1, 2025

  1. gMG

pdf

Assessing efficacy and safety of gefurulimab in generalised myasthenia gravis: baseline characteristics from PREVAIL

pdf

Assessing oral corticosteroid tapering in ravulizumab-treated adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: the phase 4, global OCTAGON study design

pdf

Concomitant immunosuppressive therapy use with ravulizumab: analysis of a generalised myasthenia gravis global registry

pdf

Corticosteroid toxicity and related healthcare resource utilization in patients with myasthenia gravis in the USA

pdf

Effectiveness and safety of ravulizumab in generalized myasthenia gravis: updated analysis from a global registry

pdf

Impact on healthcare resource utilization in early initiators of ravulizumab or efgartigimod for treatment of generalized myasthenia gravis in the USA

pdf

Longitudinal associations of corticosteroid dose with corticosteroid toxicity in patients with generalized myasthenia gravis in the USA

pdf

Oral corticosteroid use in US patients with generalized myasthenia gravis (gMG) receiving complement C5 or neonatal fc receptor

pdf

Outcomes for patients receiving ravulizumab or efgartigimod treatment within two years of generalized myasthenia gravis diagnosis: a retrospective subanalysis of US medical records

pdf

Phase 1 study evaluating gefurulimab pharmacokinetics and safety following delivery via autoinjector or prefilled syringe in healthy adults

pdf

Prediction of myasthenia gravis crisis events by a machine learning algorithm

html

Predictors of myasthenia gravis hospitalizations in the PREDICT study

html

Retrospective analysis of efgartigimod alfa-fcab or efgartigimod alfa and hyaluronidase-qvfc switches to ravulizumab in patients with myasthenia gravis

html

Retrospective analysis of intravenous immunoglobulin (IVIg) infusion switches to ravulizumab (Ultomiris) in patients with myasthenia gravis

pdf

Usability of gefurulimab autoinjector (AI) and prefilled syringe (PFS) devices: a human factors (HF) validation study

pdf

Characterization of antibiotic prophylaxis risk mitigation practices across eculizumab and ravulizumab phase 3 clinical trials in adults with PNH, aHUS, gMG, and NMOSD

pdf

Incidence and outcome of meningococcal infection with eculizumab or ravulizumab in patients with generalized myasthenia gravis or neuromyelitis optica spectrum disorder: an updated analysis of US clinical practice

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Request a field medical follow-up

Welcome to AstraZeneca
Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am not a healthcare professional practicing in the United States (Take me to AstraZeneca.com)
AstraZeneca Logo
Pharma Logo

This site is intended for healthcare professionals practicing in the US.

©2025 AstraZeneca. All rights reserved.

US-69609; US-91816; US-103094; US-106788

Last Updated 11/25

Contact Us

About Us

AstraZeneca-US.com

Grant Opportunities

Survey Feedback

Your Privacy Choices

Consumer Health Data Privacy Notice

Privacy Notice

Legal Notice

Cookie Preferences

US Site

Global Site

Report Adverse Event or Product Quality Complaint

Survey Feedback

Your Privacy Choices

Consumer Health Data Privacy Notice

Pharma Logo

Privacy NoticeLegal NoticeCookie Preferences